Abstract
Photodynamic therapy (PDT) is a new modality of skin cancer treatment. It involves the administration of photosensitizing drugs which, when localized in tumor tissue can produce its destruction by absorbing an adequate dose of light of an appropriate wavelength. A large number of photosensitizing agents have been tested in PDT experiments. Topical application of 5-aminolevulinic acid (5-ALA) followed by light irradiation is the most commonly used method. 5-ALA is a prodrug converted in situ via the heme cycle into protoporphyrin IX, an effective photosensitizer agent. Treatment of nonmelanoma skin cancers by PDT has met with varying degrees of success. In the case of 5-ALA, this therapy's main limitation is the poor penetration of 5-ALA into skin, due to hydrophilic and charge characteristics. However, the efficacy of 5-ALA-PDT may be improved by (a) development of adequate drug delivery systems; (b) use of enhancers of PpIX production and accumulation in target tissue, and (c) modifications of the 5-ALA molecule. Optimal timing, light sources, doses, and number of applications are also important factors for topical 5-ALA therapy and must be well defined. The aim of this review is to highlight recent progress in 5-ALA-PDT of skin cancer, and to present ways holding promise for its improvement.
Similar content being viewed by others
REFERENCES
H. I. Pass. Photodynamic therapy in oncology: mechanisms and clinical use. J. Natl. Cancer Inst. 85:443–456 (1993).
T. J. Dougherty, J. E. Kaufman, A. Goldfarb, K. H. Weishaupt, D. Boyle, and A. Mittleman. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 38:2628–2635 (1978).
D. J. Roberts and F. Cairnduff. Photodynamic therapy of primary skin cancer: a review. Br. J. Plast. Surgery. 48:369–370 (1995).
S. L. Gibson, J. J. Havens, M. L. Nguyen, and R. Hilf. δ-Aminolevulinic acid-induced photodynamic therapy inhibits protoporphyrin IX biosynthesis and reduces subsequent treatment efficacy in vitro. Br. J. Cancer 80:998–1004 (1999).
M. T. Bastiaens, J. J. Hoefnagel, J. Á. Bruijn, R. G. J. Westendorp, B. J. Vermeer, and J. N. B. Bavinck. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinomas indicate different types of tumors. J. Invest. Dermatol. 110:80–884 (1998).
Q. Peng, T. Warloe, J. Moan, H. Heyerdahl, H. B. Steen, J. M. Nesland, and K. E. Giercksky. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloucerative basal cell carcinoma. Photochem. Photobiol. 62:906–913 (1995).
I. M. Stender and H. C. Wulf. Photodynamic therapy with 5-aminolevulinic acid in the treatment of actinic cheilitis. Br. J. Dermatol. 135:454–456 (1996).
R. M. Szeimies and S. A. Karrer. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology 192:246–251 (1996).
A. M. Wennberg, L. E. Lindholm, M. Alpsten, and O. Larkö. Treatment of superficial basal cell carcinomas using topically applied delta-aminolevulinic acid and a filtered xenon lamp. Arch. Dermatol. Res. 288:561–564 (1996).
B. Ortel, P. G. Calzavara-Pinton, R. M. Szeimies, and T. Hasan. Perspectives in cutaneous photodynamic sensitization. J. Photochem. Photobiol. B 36:209–211 (1996).
K. Kalka, H. Merk, and H. Mukhtar. Photodynamic therapy in dermatology. J. Am. Acad. Dermatol. 42:389–413 (2000).
C. Fritsch, G. Goerz, and T. Ruzicka. Photodynamic therapy in dermatology. Arch. Dermatol. 134:207–214 (1998).
T. J. Dougherty. Photoradiation therapy for cutaneous and subcutaneous malignancies. J. Invest. Dermatol. 77:122–124 (1981).
O. Santoro, G. Bandieramonte, E. Melloni, R. Marchesini, F. Zunino, P. Lepera, and G. De Palo. Photodynamic therapy by topical mete-tetraphenylporphinesulphonate tetrasodium salt administration in superficial basal cell carcinomas. Cancer Res. 50: 4501–4503 (1990).
T. A. Katsumi, K. Aizawa, Y. Kuroiwa, K. Saito, Y. Kurata, Y. Ii, T. Okunaka, C. Konaka, and H. Kato: Photodynamic therapy with a diode laser for implanted fibrosarcoma in mice employing mono-L-aspartyl chlorin E6. Photochem. Photobiol. 64:671–675 (1996).
J. D. Spikes. New trends in photobiology: chlorins as photosensitizers in biology and medicine. J. Photochem. Photobiol. B 6: 259–274 (1990).
G. Canti, P. Franco, O. Marelli, R. Cubeddu, P. Taroni, and R. Ramponi. Comparative study of the therapeutic effect of photoactivated hematoporphyrin derivative and aluminum disulfonated phthalocyanines on tumor bearing mice. Cancer Lett. 53: 123–127 (1990).
C. Abels, R.-M. Szeimiesc, P. Steinbachd, C. Richerta, and A. E. Goetzb. Targeting of the tumor microcirculation by photodynamic therapy with a synthetic porphycene. J. Photochem. Photobiol. B 40:305–312 (1997).
M. Alecu, C. Ursaciuc, F. Halalau, G. Coman, W. Merlevede, E. Waelkens, and P. De Witte. Photodynamic treatment of basal cell carcinoma and SCC with hypericin. Anticancer Res. 18:4651–4654 (1998).
C. M. Schempp, B. Simon-Haarhaus, A. Heine, E. Schopf, and J. C. Simon. In vitro and in vivo activation of hypericin with the incoherent light source PDT 1200 SOA (520–750 nm) and with solar simulated radiation (290–2500 nm). Photodermatol. Photoimmunol. Photomed. 15:13–17 (1999).
G. Kostenich, A. Orenstein, L. Roitman, Z. Malik, and B. Ehrenberg. In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system. J. Photochem. Photobiol. B 39:36–42 (1997).
G. G. Miller, K. Brown, R. B. Moore, Z. J. Diwu, J. Liu, L. Huang, J. W. Lown, D. A. Begg, V. Chlumecky, and J. Tulip. Uptake kinetics and intracellular localization of hypocrellin photosensitizers for photodynamic therapy: a confocal microscopy study. Photochem. Photobiol. 61:632–638 (1995).
G. J. Fowler, R.C. Rees, and R. Devonshire. The photokilling of bladder carcinoma cells in vitro by phenothiazine dyes. Photochem. Photobiol. 52:489–494 (1990).
D. J. Castro, R. E. Saxton, H. R. Fetterman, D. J. Castro, and P. H. Ward. Rhodamine-123 as a new chemosensitizing versus toxic agent on human squamous carcinoma cells and fibroblast cultures. J. Clin. Laser Med. Surg. 10:83–90 (1992).
P. Wolf, E. Rieger, and H. Kerl. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. J. Am. Acad. Dermatol. 28:17–21 (1993).
F. Cairnduff, M. R. Stringer, E. J. Hudson, D.V. Ash, and S. B. Brown. Superficial photodynamic therapy with topical 5-aminolevulinic acid for superficial primary and secondary skin cancer. Br. J. Cancer 69:605–608 (1994).
Q. Peng, J. Moan, and J. M. Nesland. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruc. Pathol. 20:109–129 (1996).
J. C. Kennedy and R. H. Pottier. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J. Photochem. Photobiol. B 14:275–292 (1992).
C. Fritsch, B. Verwohlt, K. Bolsen, T. Ruzicka, and G. Goerz: Influence of topical photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism. Arch. Dermatol. Res. 288:517–521 (1996).
D. Kessel and Y. Luo. Mitochondrial photodamage and PDTinduced apoptosis. J. Photochem. Photobiol. B 42:89–95 (1998).
B. W. Henderson, and T. J. Dougherty. How does photodynamic therapy work? Photochem. Photobiol. 55:145–157 (1992).
R. M. Szeimies, P. G. Calzavara-Pinton, S. Karrer, B. Ortel, and M. Landthaler. Topical photodynamic therapy in dermatology. J. Photochem. Photobiol. B 36:213–219 (1996).
P. G. Calzavara-Pinton. Repetitive photodynamic therapy with topical δ-aminolevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J. Photochem. Photobiol. B 29:53–57 (1995).
B. A. Goff, R. Bachor, N. Kollias, and T. Hasan. Effects of photodynamic therapy with topical application of 5-aminolevulinic acid on normal skin of hairless guinea pigs. J. Photochem. Photobiol. B 15:239–251 (1992).
R. M. Szeimies, R. Hein, W. Baümler, A. Heine, and M. Landthaler. A possible new incoherent lamp for photodynamic treatment of superficial skin lesions. Acta Dermatol. Venereol. 59:73–76 (1994).
R. M. Szeimies, C. Abels, C. Fritsch, S. Karrer, P. Steinbach, W. Baumler, G. Goerz, A. E. Goetz, and M. Landthaler. Wavelength dependency of photodynamic effects after sensitization with 5-aminolevulinic acid in vitro and in vivo. J. Invest. Dermatol. 105:672–677 (1995).
P. Charlesworth and T. G. Truscott. The use of 5-aminolevulinic acid (ALA) in photodynamic therapy. J. Photochem. Photobiol. B 18:99–100 (1993).
W. M. Star. Light dosimetry in vivo. Phys. Med. Biol. 42:763–787 (1997).
J. C. Kennedy, R. H. Pottier, and D. C. Pross, Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J. Photochem. Photobiol. B 6:143–148 (1990).
D. X. G. Divaris, J. C. Kennedy, and R. H. Pottier. Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. Am. J. Pathol. 136:891–897 (1990).
P. Wolf and H. Kerl. Photodynamic therapy with 5-aminolevulinic acid: a promising concept for the treatment of cutaneous tumors. Dermatology 190:183–185 (1995).
C. Abels, P. Heil, M. Dellian, G. E. H. Kuhnle, R. Baumgartner, and A. E. Goetz. In vivo kinetics and spectra of 5-aminolevulinic acid-induced fluorescence in an amelanotic melanoma of the hamster. Br. J. Cancer 70:826–833 (1994).
M. Kriegmeir, R. Baumgartner, R. Kneuchel, H. Stepp, F. Hofsteder, and A. Hofstetter. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J. Urol. 155:105–110 (1996).
Ø. Bech, K. Berg, and J. Moan. The pH dependency of protoporphyrin IX formation in cells incubated with 5-aminolevulinic acid. Cancer Lett. 113:25–29 (1997).
S. L. Gibson, D. J. Cupriks, J. J. Havens, M. L. Nguyen, and R. Hilf. A regulatory role for porphobilinogen deaminase (PBGD) in δ-aminolevulinic acid (d-5-ALA)-induced photosensitization? Br. J. Cancer 77:235–243 (1998).
O. Trepte, I. Rokahr, S. Anderson-Engels, and K. Carlsson. Studies of porphyrin-containing specimens using an optical spectrometer connected to a confocal scanning laser microscope. J. Microscopy 176:238–244 (1994).
S. Iinuma, S. S. Farshi, B. Ortel, and T. Hasan. A mechanistic study of cellular photodestruction with 5-aminolevulinic acidinduced porphyrin. Br. J. Cancer 70:21–28 (1994).
K. Tabata, S. Ogura, and I. Okura. Photodynamic efficiency of protoporphyrin IX: comparison of endogenous protoporphyrin IX induced by 5-aminolevulinic acid and exogenous porphyrin IX. Photochem. Photobiol. 66:842–846 (1997).
B. C. Wilson and G. Sngh. Subcellular localization of Photfrin and aminolevulinic acid and photodynamic cross-resistance in vitro in radiation-induced fibrosarcoma cells sensitive or resistant to Photofrin-mediated photodynamic therapy. Photochem. Photobiol. 65:166–176 (1997).
J. J. Schuitmaker, P. Baas, H. L. L. M. Van Leengoed, F. W. Van Der Meulen, W. M. Star, and N. Van Zandwijk. Photodynamic therapy: a promising new modality for the treatment of cancer. J. Photochem. Photobiol. B 34:3–12 (1996).
K. Svanberg, T. Anderson, D. Killander, I. Wang, U. Stenram, S. Andersson-Engels, R. Berg, J. Johansson, and S. Svanberg. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical δ-aminolevulinic acid sensitization and laser irradiation. Br. J. Dermatol. 130:743–751 (1994).
C. A. Morton, C. Whitehurst, H. Moseley, J. H. Mccoll, J. V. Moore, and R. Mackie. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br. J. Dermatol. 135:766–771 (1996).
E. W. Jeffes, J. L. Mccullough, G. D. Weinstein, P. E. Fergin, J. S. Nelson, T. F. Shull, K. R. Simpson, L. M. Bukaty, W. L. Hoffman, and N. L. Fong. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. Arch. Dermatol. 133:727–732 (1997).
A. F. Hürlimann, G. Hänggi, and R. G. Panizzon. Photodynamic therapy of superficial basal cell carcinomas using topical aminolevulinic acid in a nanocolloid lotion. Dermatology 197:248–254 (1998).
C. Fritsch, C. Abels, A. E. Goetz, W. Stahl, K. Bolsen, T. Ruzicka, G. Goerz, and H. Sies. Porphyrins preferentially accumulate in a melanoma following intravenous injaction of 5-aminolevulinic acid. Biol. Chem. 378:51–57 (1997).
M. R. Stringer, P. Collins, D. J. Robinson, G. I. Stables, and R. A. Sheehan-Dare. The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. J. Invest. Dermatol. 107:76–81 (1996).
G. I. Stables, M. R. Stringer, D. J. Robinson, and D. V. Ash. Large patches of Bowen's disease treated by topical aminolevulinic acid photodynamic therapy. Br. J. Dermatol. 136:957–960 (1997).
P. Ziolkowski, K. Symonowicz, P. Chmielewski, L. Latos-Grazynski, G. Streckyte, R. Rotomskis, and J. Rabczynski. New potent sensitizers for photodynamic therapy: 21-oxaporphyrin, 21-thiaporphyrin and 21,23-dithiaporphyrin induce extensive tumor necrosis. J. Cancer Res. Clin. Oncol. 125:563–568 (1999).
E. Reddi. Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours. J. Photochem. Photobiol. B 37:189–195 (1997).
Z. J. Wang, Y. Y. He, C. G. Huang, J. S. Huang, Y. C. Huang, J. Y. An. Y. Gu, and L. J. Jiang. Pharmacokinetics, tissue distribution and photodynamic therapy efficacy of liposomal-delivered hypocrellin A, a potential photosensitizer for tumor therapy. Photochem. Photobiol. 70:773–780 (1999).
J. Kloek, W. Akkermans, and G. M. J. B. Van Henegouwen. Derivatives of 5-aminolevulinic acid for Photodynamic Therapy: enzymatic conversion into protoporphyrin. Photochem. Photobiol. 67:150–154 (1998).
A. C. William and B. W. Barry. Skin absorption enhancers. Crit. Ver. Ther. Drug Carrier Syst. 9:305–353 (1992).
M. V. L. B. Bentley, R. F. Vianna, S. Wilson, and J. H. Collett. A characterisation of the influence of some cyclodextrins on the stratum corneum from the hairless mouse. J. Pharm. Pharmacol. 49:397–402 (1997).
N. Schoenfeld, R. Mamet, Y. Nordenberg, M. Shafran, T. Babushkin, and Z. Malik. Protoporphyrin biosynthesis in melanoma B16 cells stimulated by 5-aminolevulinic acid and chemical inducers: characterization of photodynamic inactivation. Int. J. Cancer 56:106–112 (1994).
H. Fujita, M. Yamamoto, T. Yamagami, N. Hayashi, T.R. Bishop, H. De Verneuil, T. Yoshinaga, S. Shibahara, R. Morimoto, and S. Sassa. Sequential activation of genes for heme pathway enzymes during erythroid differentiation of mouse Friend virus-transformed erythroleukemia cells. Biochem. Biophys. Acta 1090: 311–316 (1991).
A. N. C. Anigbogu, A. C. Williams, B. W. Barry, and H. G. M. Edwards. Fourier transform Raman spectroscopy of interactions between the penetration enhancer dimethylsulfoxide and human stratum corneum. Int. J. Pharm. 125:265–282 (1995).
J. Hanania and Z. Malik. The effect of EDTA and serum on endogenous-porphyrin accumulation and photodynamic sensitization of human K562 leukemic cells. Cancer Lett. 65:127–131 (1992).
F. S. De Rosa, J. M. Marchetti, J. A. Thomazini, A. C. Tedesco, and M. V. L. B. Bentley. A vehicle for photodynamic therapy of skin cancer:influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J. Controlled Release 65:359–366 (2000).
Z. Malik, G. Kostenich, L. Roitman, B. Ehrenberg, and A. Orenstein. Topical application of 5-aminolevulinic acid, DMSO, and EDTA: protoporphyrin IX accumulation in skin and tumors of mice. J. Photochem. Photobiol. B 28: 213–218 (1995).
Y. Harth, B. Hirshowitz, and B. Kaplan. Modified topical photodynamic therapy of superficial skin tumors, utilizing aminolevulinic acid, penetration enhancers, red light, and hyperthermia, Dermatol. Surg. 24: 723–726 (1998).
A. M. Soler, T. Warloe, J. Tausjo, and A. Berner. Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodularbasal cell carcinoma: a one-year follow-up study. Acta Derm. Venereol. (Stockh.) 79:204–206 (1999).
S. Fijan, H. Hönigsmann, and B. Ortel. Photodynamic therapy of epithelial skin tumours using delta-aminolevulinic acid and desferrioxamine. Br. J. Dermatol. 133:282–288 (1995).
D. Letourneur, C. Parisel, S. Pringent-Richard, and M. Cansell. Interactions of funcionalized dextran-coated liposomes with vascular smooth muscle cells. J. Controlled Release 65:83–91 (2000).
H. Fukuda, S. Paredes, and A.M. D. C. Batlle. Tumour-localizing properties of porphyrins. In vitro studies using porphyrin precursor, aminolevulinic acid, in free and liposome encapsulated forms. Drug. Des. Deliv. 5:133–139 (1989).
H. Fukuda, S. Paredes, and A.M. D. C. Batlle. Tumour-localizing properties of porphyrins. In vivo studies using free and liposome encapsulated aminolevulinic acid. Comp. Biochem. Physiol. 102B:433–436 (1992).
J. Kloek and G. M. J. B. Van Henegouwen. Prodrugs of 5-aminolevulinic acid for Photodynamic Therapy. Photochem. Photobiol. 64:994–1000 (1996).
Q. Peng, J. Moan, T. Warloe, V. Iani, H. B. Stenn, A. Bjørseth, and J. M. Nesland. Buid-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. J. Photochem. Photobiol. B 34:95–96 (1996).
J.-M. Gaullier, K. Berg, Q. Peng, H. Anholt, P. K. Selbo, L.-W. Ma, and J. Moan. Use of 5-aminolevulinic acid esters to improve Photodynamic Therapy on cells in culture. Cancer Res. 57:1481–1486 (1997).
R. H. Guy, Y. N. Kalia, M. B. Delgado-Charro, V. Merino, A. Lopez, and D. Marro. Iontophoresis: electrorepulsion and electroosmosis. J. Controlled Release 64:129–132 (2000).
L. Rhodes, M. T. Tsoukas, R. R. Anderson, and N. Kollias. Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. J. Invest. Dermatol. 108:87–91 (1997).
R. F. V. Lopez, M. V. L. B. Bentley, M. B. Delgado-Charro, and R. H. Guy. Iontophoretic delivery of 5-aminolevulinic acid (ALA): effect of pH. Proc. Int. Symp. Controlled Release Bioact. Mater. 27 (2000), in press.
L. Ma, J. Moan, Q. Peng, and V. Iani. Production of protoporphyrin IX induced by 5-aminolevulinic acid in transplanted human colonadenocarcinoma of nude mice can be increased by ultrasound. Int. J. Cancer 78:464–469 (1998.).
N. Van Der Veen, H. S. De Bruijn, and W. M. Star. Photobleaching during and re-appearance after photodynamic therapy of topical 5-ALA-induced fluorescence in UVB-treated mouse skin. Int. J. Cancer 72:110–118 (1997).
H. Messmann, P. Mlkvy, G. Buonaccorso, C. L. Davies, A. J. Macrobert, and S. G. Bown. Enhancement of photodynamic therapy with 5-aminolevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. Br. J. Cancer 72:589–594 (1995).
A. Curnow, B. W. Mcilroy, M. J. Postle-Hacon, A. J. Macrobert, and S. G. Bown. Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon. Photochem. Photobiol. 69:71–76 (1999).
H. S. De Bruijn, N. Van der Veen, D. J. Robinson, and W. M. Star. Improvement of systemic 5-aminolevulinic acid-based photodynamic therapy in vivo using light fractionation with a 75-minute interval. Cancer Res. 59:901–904 (1999).
J. Moan, K. Berg, O. Gadmar, V. Biani, L. Ma, and P. Juzenas. The temperature dependence of protoporphyrin IX production in cells and tissues. Photochem. Photobiol. 70:669–673 (1999).
P. Juzenas, R. Sorensen, V. Iani, and J. Moan. Uptake of topically applied of 5-aminolevulinic acid and production of protoporphyrin IX in normal mouse skin: dependence on skin temperature. Photochem. Photobiol. 69:478–481 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De Rosa, F.S., Bentley, M.V.L.B. Photodynamic Therapy of Skin Cancers: Sensitizers, Clinical Studies and Future Directives. Pharm Res 17, 1447–1455 (2000). https://doi.org/10.1023/A:1007612905378
Issue Date:
DOI: https://doi.org/10.1023/A:1007612905378